

eatris

European infrastructure
for translational medicine

Collaboration opportunities with EATRIS

07-03-2025

Martin de Kort, PhD

martindekort@eatris.eu



Successful R&I in Europe 2025, 12th European Networking Event

Düsseldorf

Who we are

Facilities, resources and services to support cutting edge research



EATRIS countries

Bulgaria, Croatia, Czech Republic, Finland, France, Italy, Latvia, Luxembourg, Netherlands, Norway, Portugal, Slovenia, Spain, Sweden



155
Research Institutes



5 Scientific Platforms

- ATMPs
- Biomarker
- Imaging & Tracing
- Small Molecules
- Vaccine, inflammation and immune monitoring



Legal status
Non-profit, ERIC legal status

Examples of key actions



Support for funding applications (1)

EATRIS offers a range of resources to **help researchers strengthen the translational potential** of their research proposals

1



**FORMING A
CONSORTIUM**

2



**JOINING AS A
PARTNER**

3




**LEADING FLAGSHIP
PROJECTS**

Support for funding applications (2)

EATRIS can join research funding applications as a full partner, offering **tailored translational expertise to support your proposal**

2A




**INNOVATION
MANAGEMENT
& INDUSTRY
PARTNERING**

2B



**REGULATORY
SUPPORT**

2C



**TRANSLATIONAL
OPTIMISATION**

2D



**TRAINING
WORKSHOPS**


Flagship projects (3)



ATMP Development



Drug Repurposing



preciseu.eu/

Do you have a drug repurposing project? Let's talk and see how we can help!


remedi4all.org/repurposing-concierge/

An accessible EU drug repurposing platform



remedi4all.org

Therapeutic Hypothesis for repurposing a specific drug



#iDR25

INTERNATIONAL DRUG REPURPOSING CONFERENCE

Medicines Reimagined

Unlocking the Potential of Existing Drugs for Patient Benefit

ORGANISED BY

HEADLINE SPONSOR



Funded by
the European Union

The REMEDI4ALL project has received funding from the European Union's Horizon Europe Research & Innovation programme under grant agreement No 101057442.

Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union or European Research Executive Agency. Neither the European Union nor the granting authority can be held responsible for them.



SCAN ME



With thanks to our funders and partners



REPUBLIC OF BULGARIA
Ministry of Education and Science

Republic of Bulgaria
Ministry of Education and Science



REPUBLIC OF CROATIA
Ministry of Science and Education

Republic of Croatia
Ministry of Science and Education



MINISTRY OF EDUCATION,
YOUTH AND SPORTS

Czech Republic
Ministry of Education, Youth & Sports



**Research Council
of Finland**

Republic of Finland
Research Council of Finland



French Republic
Commissariat à l'Énergie Atomique et aux
Énergies Alternatives (CEA)



Italian Republic
Istituto Superiore di Sanità (ISS)



Republic of Latvia
Ministry of Education and Science



LE GOUVERNEMENT
DU GRAND-DUCHÉ DE LUXEMBOURG
Ministère de l'Enseignement supérieur
et de la Recherche

Kingdom of Luxembourg
Le Gouvernement du grand-duché de
Luxembourg



Kingdom of the Netherlands
ZonMW



Kingdom of Norway
Research Council of Norway*



UNIVERSITETET
I OSLO

Kingdom of Norway
University of Oslo*



Autoridade Nacional do Medicamento
e Produtos de Saúde, I.P.

Republic of Portugal
INFARMED-National Authority of
Medicines and Health Products



REPUBLIC OF SLOVENIA
MINISTRY OF HIGHER EDUCATION,
SCIENCE AND INNOVATION

Republic of Slovenia
Ministry of Higher Education,
Science and Innovation



Kingdom of Spain
Instituto de Salud 'Carlos III' (ISCIII)



Swedish
Research
Council

Kingdom of Sweden
Vetenskapsrådet**



Kingdom of Sweden
Vinnova**

*The contribution from Norway is from the University of Oslo

**The Swedish contribution is from Vinnova